HK Stock MarketDetailed Quotes
06855 ASCENTAGE-B
- 17.620
- +0.320+1.85%
Market Closed Apr 26 16:08 CST
5.11BMarket Cap-5005P/E (TTM)
17.800High17.300Low615.10KVolume17.300Open17.300Pre Close10.84MTurnover0.21%Turnover RatioLossP/E (Static)290.21MShares28.15052wk High76.61P/B5.11BFloat Cap15.42052wk Low--Dividend TTM290.21MShs Float58.200Historical High--Dividend LFY2.89%Amplitude11.160Historical Low17.617Avg Price100Lot Size--Div YieldTTM--Div Yield LFY
About ASCENTAGE-B Company
Ascorbic Pharma is a globally focused clinical-stage biotechnology company dedicated to developing novel therapies for cancer, the hepatitis B virus, and age-related diseases. The company focuses on developing treatments that inhibit protein-protein interactions to restore apoptosis or programmed cell death. Ascorbic Pharma has established new products including eight drug candidates, including novel, highly effective Bcl-2/Bcl-XL inhibitors, candidates targeting the IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. The company has conducted 28 phase I/II clinical trials to evaluate eight products from the US, Australia, and China to develop potential treatments as single drugs or combination drugs.
Company Profile
Symbol06855
Company NameASCENTAGE-B
ISINKYG0519B1023
Listing DateOct 28, 2019
Issue Price34.20
Shares Offered12.18M share(s)
FoundedNov 17, 2017
Registered AddressCayman Islands
Chairmandajun yang
Secretaryzhangqi wang
Audit InstitutionErnst & Young
Company CategoryOther
Registered OfficeWalkers Corporate Limited Cayman Corporate Centre 27 Hospital Road George Town Grand Cayman KY1-9008 Cayman Islands
Head Office and Principal Place of BusinessUnit B, 17th floor, United Centre, 95 Queensway, Admiralty, Hong Kong
Fiscal Year Ends12-31
Employees583
MarketHong Kong motherboard
Phone(86)51285557777
EmailIR@ascentage.com
Websitehttp://www.ascentage.cn
Business Yasheng Pharmaceutical Group is an investment holding company mainly engaged in developing innovative microtherapeutics for cancer, hepatitis B virus and several age-related diseases. The company has a self-developed drug design platform targeting protein-protein interactions. The company's main products include next-generation kinase inhibitor HQP1351, apoptosis targeting drugs APG-1252, APG2575, APG-115, etc. The company operates in domestic markets and overseas markets such as the US.
Company Executives
- Name
- Position
- Salary
- dajun yang
- CEOs，Chairman of the Board，Executive Director，Chairman of the Nomination Committee，Remuneration Committee Members，Authorized Representative
- --
- shaomeng wang
- Chairman of the Scientific Advisory Board，Non-executive directors
- --
- dazhong lv
- Non-executive directors，Audit Committee Members
- --
- zhangqing ye
- Independent Non-Executive Director，Chairman of the Audit Committee，Nomination Committee Members
- --
- zheng yin
- Independent Non-Executive Director，Remuneration Committee Chairman，Audit Committee Members
- --
- wei ren
- Independent Non-Executive Director，Remuneration Committee Members，Nomination Committee Members
- --
- David Sidransky
- Independent Non-Executive Director
- --
- yifan di
- Chief Medical Officer
- --
- Raymond Jeffrey KMETZ
- Chief Commercial Officer
- --
- Thomas Joseph KNAPP
- senior vice president，General Counsel
- --
- yiqing chen
- chief financial officer
- --
- gang zhu
- Chief Commercial Operations Officer
- --
- zhangqi wang
- Company Secretary，Authorized Representative
- --
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
%Chg